# ABC Transporters, APOE, CYP46A1, and LRP1 Gene Polymorphisms as Markers of Dementia Development in Patients with Hyperlipidemia

**Authors:** Marta Machowska, Jerzy Leszek, Maja Rączy-Krzemianowska, Beata Tomasiewicz, Magdalena Hurkacz, Małgorzata Rąpała, Janusz Piechota, Krystyna Głowacka, Anna Wiela-Hojeńska

PMC · DOI: 10.3390/ijms262110759 · International Journal of Molecular Sciences · 2025-11-05

## TL;DR

This study explores how gene variations in patients with high cholesterol can help identify those at higher risk of developing dementia, especially Alzheimer's disease.

## Contribution

The study identifies ABCA1 rs2230806 as a potential early marker for dementia risk in hyperlipidemic patients.

## Key findings

- The GG genotype of ABCA1 rs2230806 was more common in dementia patients, particularly those with Alzheimer’s disease.
- The G allele showed a higher frequency in dementia patients compared to controls.
- The GG genotype was associated with shorter disease duration and worse cognitive scores in early stages.

## Abstract

In an aging society, solving problems associated with the diagnosis and treatment of dementia-related diseases represents a serious challenge. The aim of the study was to evaluate the possibility of applying molecular biology methods to test polymorphisms recognized in the global literature as potentially useful in assessing the risk of developing dementia in a group of patients with hyperlipidemia. A sample of 203 patients: 109 diagnosed with both dementia and hyperlipidemia, 94 with hyperlipidemia, and 101 individuals as an allele frequency control group—were genotyped. Additional data about cognitive decline and neuropsychological assessment were collected. Among all the studied polymorphisms, the frequency of the ABCA1 rs2230806 polymorphism differed between the analyzed groups. The GG genotype (p = 0.0002, RR = 3.22, CI = 1.63 ÷ 6.37) and the G allele (p = 0.0007, RR = 1.53, CI = 1.19 ÷ 1.97) were more frequent in patients diagnosed with dementia, specifically in those with Alzheimer’s disease. Furthermore, the GG genotype was more common in individuals with a shorter disease duration and lower scores on the Montreal Cognitive Assessment (MoCA) scale, and consequently, with greater cognitive function deficits during early stages of the diagnostic process. ABCA1 rs2230806 genotyping is a potential marker for the early identification of dementia risk in patients with hyperlipidemia, which supports the validity of exploring options for incorporating diagnostics based on molecular biology methods.

## Linked entities

- **Genes:** ABCA1 (ATP binding cassette subfamily A member 1) [NCBI Gene 19], APOE (apolipoprotein E) [NCBI Gene 348], CYP46A1 (cytochrome P450 family 46 subfamily A member 1) [NCBI Gene 10858], LRP1 (LDL receptor related protein 1) [NCBI Gene 4035]
- **Diseases:** dementia (MONDO:0001627), hyperlipidemia (MONDO:0021187), Alzheimer’s disease (MONDO:0004975)

## Full-text entities

- **Genes:** ABCA1 (ATP binding cassette subfamily A member 1) [NCBI Gene 19] {aka ABC-1, ABC1, CERP, HDLCQTL13, HDLDT1, HPALP1}, CYP46A1 (cytochrome P450 family 46 subfamily A member 1) [NCBI Gene 10858] {aka CP46, CYP46}, LRP1 (LDL receptor related protein 1) [NCBI Gene 4035] {aka A2MR, APOER, APR, CD91, DDH3, IGFBP-3R}, APOE (apolipoprotein E) [NCBI Gene 348] {aka AD2, APO-E, ApoE4, LDLCQ5, LPG}
- **Diseases:** cognitive decline (MESH:D003072), Hyperlipidemia (MESH:D006949), Alzheimer's disease (MESH:D000544), Dementia (MESH:D003704)
- **Species:** Homo sapiens (human, species) [taxon 9606]
- **Mutations:** rs2230806

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12608497/full.md

## Figures

1 figure with captions in the complete paper: https://tomesphere.com/paper/PMC12608497/full.md

## References

36 references — full list in the complete paper: https://tomesphere.com/paper/PMC12608497/full.md

---
Source: https://tomesphere.com/paper/PMC12608497